{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:49Z","timestamp":1787020789051,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["777500"],"award-info":[{"award-number":["777500"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>IMI2-PainCare-BioPain-RCT2 is one of four similarly designed clinical studies aiming at profiling a set of functional biomarkers of drug effects on specific compartments of the nociceptive system that could serve to accelerate the future development of analgesics. IMI2-PainCare-BioPain-RCT2 will focus on human spinal cord and brainstem activity using biomarkers derived from non-invasive neurophysiological measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a multisite, single-dose, double-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD) and pharmacokinetic (PK) study in healthy subjects. Neurophysiological biomarkers of spinal and brainstem activity (the RIII flexion reflex, the N13 component of somatosensory evoked potentials (SEP) and the R2 component of the blink reflex) will be recorded before and at three distinct time points after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol), and placebo, given as a single oral dose in separate study periods. Medication effects on neurophysiological measures will be assessed in a clinically relevant hyperalgesic condition (high-frequency electrical stimulation of the skin), and in a non-sensitized normal condition. Patient-reported outcome measures (pain ratings and predictive psychological traits) will also be collected; and blood samples will be taken for pharmacokinetic modelling. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split between the two primary endpoints, namely the percentage amplitude changes of the RIII area and N13 amplitude under tapentadol. Remaining treatment arm effects on RIII, N13 and R2 recovery cycle are key secondary confirmatory analyses. Complex statistical analyses and PK-PD modelling are exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The RIII component of the flexion reflex is a pure nociceptive spinal reflex widely used for investigating pain processing at the spinal level. It is sensitive to different experimental pain models and to the antinociceptive activity of drugs. The N13 is mediated by large myelinated non-nociceptive fibers and reflects segmental postsynaptic response of wide dynamic range dorsal horn neurons at the level of cervical spinal cord, and it could be therefore sensitive to the action of drugs specifically targeting the dorsal horn. The R2 reflex is mediated by large myelinated non-nociceptive fibers, its circuit consists of a polysynaptic chain lying in the reticular formation of the pons and medulla. The recovery cycle of R2 is widely used for assessing brainstem excitability. For these reasons, IMI2-PainCare-BioPain-RCT2 hypothesizes that spinal and brainstem neurophysiological measures can serve as biomarkers of target engagement of analgesic drugs for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      This trial was registered on 02 February 2019 in EudraCT (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000755-14\/IT\">2019-000755-14<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-022-06431-5","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T03:05:55Z","timestamp":1662347155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8828-361X","authenticated-orcid":false,"given":"Caterina","family":"Leone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Bloms-Funke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmgard","family":"Boesl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Caspani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya C.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna Brix","family":"Finnerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Garcia-Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Mouraux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Pelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Pogatzki-Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Schnetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Schubart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tracey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inaki F.","family":"Troconiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Van Niel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Miguel Vela","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vollert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvarani","family":"Wanigasekera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Wittayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith G.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Truini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf-Detlef","family":"Treede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"issue":"4","key":"6431_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/j.pain.0000000000000454","volume":"157","author":"ASC Rice","year":"2016","unstructured":"Rice ASC, Smith BH, Blyth FM. Pain and the global burden of disease. Pain. 2016;157(4):791\u20136.","journal-title":"Pain"},{"key":"6431_CR2","doi-asserted-by":"crossref","unstructured":"Mouraux A, Bloms-Funke P, Boesl I, Caspani O, Chapman SC, Di Stefano G, et al. IMI2-PainCare-BioPain-RCT3: a randomized double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG). Trials. 2021; In press.","DOI":"10.1186\/s13063-021-05272-y"},{"key":"6431_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pneurobio.2005.11.003","volume":"77","author":"G Sandrini","year":"2005","unstructured":"Sandrini G, Serrao M, Rossi P, Romaniello A, Cruccu G, Willer JC. The lower limb flexion reflex in humans. Prog Neurobiol. 2005;77:353\u201395.","journal-title":"Prog Neurobiol"},{"issue":"12","key":"6431_CR4","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1016\/j.clinph.2021.08.018","volume":"132","author":"C Leone","year":"2021","unstructured":"Leone C, Di Lionardo A, Di Pietro G, Di Stefano G, Falco P, Blockeel AJ, et al. How different experimental models of secondary hyperalgesia change the nociceptive flexion reflex. Clin Neurophysiol. 2021;132(12):2989\u201395.","journal-title":"Clin Neurophysiol"},{"key":"6431_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/brain\/114.1.361","volume":"114","author":"D Restuccia","year":"1991","unstructured":"Restuccia D, Maugui\u00e8re F. The contribution of median nerve SEPs in the functional assessment of the cervical spinal cord in syringomyelia. A study of 24 patients. Brain. 1991;114:361\u201379.","journal-title":"Brain"},{"key":"6431_CR6","doi-asserted-by":"publisher","unstructured":"Di Pietro G, Di Stefano G, Leone C, Lionardo AD, Sgr\u00f2 E, Blockeel AJ, et al. The N13 spinal component of somatosensory evoked potentials is modulated by heterotopic noxious conditioning stimulation suggesting an involvement of spinal wide dynamic range neurons. Neurophysiol Clin. 2021;51(6):517-23. https:\/\/doi.org\/10.1016\/j.neudi.2021.09.001.","DOI":"10.1016\/j.neudi.2021.09.001"},{"key":"6431_CR7","doi-asserted-by":"publisher","unstructured":"Cruccu G, Deuschl G. The clinical use of brainstem reflexes and hand-muscle reflexes. Clin Neurophysiol. 2000;111(3):371-87. https:\/\/doi.org\/10.1016\/s1388-2457(99)002191-6.","DOI":"10.1016\/s1388-2457(99)002191-6"},{"issue":"1","key":"6431_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/brain\/96.1.87","volume":"96","author":"J Kimura","year":"1973","unstructured":"Kimura J. Disorder of interneurons in Parkinsonism. The orbicularis oculi reflex to paired stimuli. Brain. 1973;96(1):87\u201396. https:\/\/doi.org\/10.1093\/brain\/96.1.87 PMID: 4695726.","journal-title":"Brain"},{"issue":"4","key":"6431_CR9","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1523\/JNEUROSCI.1222-03.2004","volume":"24","author":"T Klein","year":"2004","unstructured":"Klein T, Magerl W, Hopf HC, Sandkuhler J, Treede RD. Perceptual correlates of nociceptive long-term potentiation and long-term depression in humans. J Neurosci. 2004;24(4):964\u201371.","journal-title":"J Neurosci"},{"issue":"7","key":"6431_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/ejp.1768","volume":"25","author":"C Quesada","year":"2021","unstructured":"Quesada C, Kostenko A, Ho I, Leone C, Nochi Z, Stouffs A, et al. Human surrogate models of central sensitization: a critical review and practical guide. Eur J Pain. 2021;25(7):1389\u2013428.","journal-title":"Eur J Pain"},{"issue":"9","key":"6431_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1517\/13543784.2010.511174","volume":"19","author":"G McCleane","year":"2010","unstructured":"McCleane G. Lacosamide for pain. Expert Opin Investig Drugs. 2010;19(9):1129\u201334.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"6431_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2337\/dc09-1578","volume":"33","author":"D Ziegler","year":"2010","unstructured":"Ziegler D, Hidvegi T, Gurieva I, Bongardt S, Freynhagen R, Sen D, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care. 2010;33(4):839\u201341.","journal-title":"Diabetes Care"},{"issue":"8","key":"6431_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jpain.2009.01.322","volume":"10","author":"A Shaibani","year":"2009","unstructured":"Shaibani A, Fares S, Selam J-L, Arslanian A, Simpson J, Sen D, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain. 2009;10(8):818\u201328.","journal-title":"J Pain"},{"issue":"2","key":"6431_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/01.ajp.0000210957.39621.b2","volume":"23","author":"RL Rauck","year":"2007","unstructured":"Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007;23(2):150\u20138.","journal-title":"Clin J Pain"},{"issue":"5","key":"6431_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/AJP.0b013e318196d2b6","volume":"25","author":"JP Wymer","year":"2009","unstructured":"Wymer JP, Simpson J, Sen D, Bongardt S. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 2009;25(5):376\u201385.","journal-title":"Clin J Pain"},{"issue":"2","key":"6431_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/brain\/awy329","volume":"142","author":"BTA de Greef","year":"2019","unstructured":"de Greef BTA, Hoeijmakers JGJ, Geerts M, Oakes M, Church TJE, Waxman SG, et al. Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain. 2019;142(2):263\u201375.","journal-title":"Brain"},{"key":"6431_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ebiom.2018.11.042","volume":"39","author":"B Namer","year":"2019","unstructured":"Namer B, Schmidt D, Eberhardt E, Maroni M, Dorfmeister E, Kleggetveit IP, et al. Pain relief in a neuropathy patient by lacosamide: proof of principle of clinical translation from patient-specific iPS cell-derived nociceptors. EBioMedicine. 2019;39:401\u20138.","journal-title":"EBioMedicine"},{"issue":"1","key":"6431_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1528-1167.2012.03725.x","volume":"54","author":"W Cawello","year":"2013","unstructured":"Cawello W, B\u00f6kens H, Nickel B, Andreas J-O, Halabi A. Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment: LCM Tablet\/Syrup Bioequiv and Saliva PK. Epilepsia. 2013;54(1):81\u20138.","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"6431_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000339077","volume":"90","author":"W Cawello","year":"2012","unstructured":"Cawello W, Bonn R, Boekens H. Bioequivalence of intravenous and oral formulations of the antiepileptic drug lacosamide. Pharmacology. 2012;90(1\u20132):40\u20136.","journal-title":"Pharmacology"},{"issue":"8","key":"6431_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1177\/0091270009352087","volume":"50","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50(8):941\u201350.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"6431_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40261-014-0211-4","volume":"34","author":"ML Chew","year":"2014","unstructured":"Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, et al. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. Clin Drug Investig. 2014;34(9):617\u201326.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"6431_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40268-015-0094-8","volume":"15","author":"A Filipe","year":"2015","unstructured":"Filipe A, Almeida S, Pedroso PF, Neves R, Marques S, Sicard E, et al. Single-dose, randomized, open-label, two-way, crossover bioequivalence study of two formulations of pregabalin 300 mg hard capsules in healthy volunteers under fasting conditions. Drugs R D. 2015;15(2):195\u2013201.","journal-title":"Drugs R D"},{"issue":"6","key":"6431_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/AAP.0b013e3181fa6b7a","volume":"35","author":"A Buvanendran","year":"2010","unstructured":"Buvanendran A, Kroin JS, Kari M, Tuman KJ. Can a single dose of 300 mg of pregabalin reach acute antihyperalgesic levels in the central nervous system? Reg Anesth Pain Med. 2010;35(6):535\u20138.","journal-title":"Reg Anesth Pain Med"},{"issue":"1","key":"6431_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1185\/03007995.2010.537589","volume":"27","author":"S Schwartz","year":"2011","unstructured":"Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151\u201362.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"6431_CR25","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.2337\/dc13-2291","volume":"37","author":"AI Vinik","year":"2014","unstructured":"Vinik AI, Shapiro DY, Rauschkolb C, Lange B, Karcher K, Pennett D, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37(8):2302\u20139.","journal-title":"Diabetes Care"},{"issue":"7","key":"6431_CR26","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.pain.2011.02.037","volume":"152","author":"DB Pfau","year":"2011","unstructured":"Pfau DB, Klein T, Putzer D, Pogatzki-Zahn EM, Treede RD, Magerl W. Analysis of hyperalgesia time courses in humans after painful electrical high-frequency stimulation identifies a possible transition from early to late LTP-like pain plasticity. Pain. 2011;152(7):1532\u20139.","journal-title":"Pain"},{"issue":"1","key":"6431_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0006-8993(85)90719-X","volume":"331","author":"JC Willer","year":"1985","unstructured":"Willer JC. Studies on pain. Effects of morphine on a spinal nociceptive flexion reflex and related pain sensation in man. Brain Res. 1985;331(1):105\u201314.","journal-title":"Brain Res"},{"issue":"8","key":"6431_CR28","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.clinthera.2007.08.007","volume":"29","author":"M Escher","year":"2007","unstructured":"Escher M, Daali Y, Chabert J, Hopfgartner G, Dayer P, Desmeules J. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. Clin Ther. 2007;29(8):1620\u201331.","journal-title":"Clin Ther"},{"key":"6431_CR29","first-page":"35","volume-title":"Measures in health psychology: a user\u2019s portfolio causal and control beliefs","author":"R Schwarzer","year":"1995","unstructured":"Schwarzer R, Jerusalem M. Generalized self-efficacy scale. In: Weinman J, Wright S, Johnston M, editors. Measures in health psychology: a user\u2019s portfolio causal and control beliefs. Windsor: NFER-NELSON; 1995. p. 35\u20137."},{"issue":"4","key":"6431_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1037\/1040-3590.7.4.524","volume":"7","author":"MJL Sullivan","year":"1995","unstructured":"Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess. 1995;7(4):9.","journal-title":"Psychol Assess"},{"issue":"1","key":"6431_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pain.2009.06.020","volume":"146","author":"R Ruscheweyh","year":"2009","unstructured":"Ruscheweyh R, Marziniak M, Stumpenhorst F, Reinholz J, Knecht S. Pain sensitivity can be assessed by self-rating: development and validation of the Pain Sensitivity Questionnaire. Pain. 2009;146(1):65\u201374.","journal-title":"Pain"},{"key":"6431_CR32","unstructured":"Spielberger CD, Gorsuch RL, Lushene RL, Vagg PR, Jacobs GA. Manual for the state-trait anxiety inventory. Palo Alto: Consulting Psychologists Press; 1983."},{"issue":"4","key":"6431_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/sim.3495","volume":"28","author":"F Bretz","year":"2009","unstructured":"Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Statist Med. 2009;28(4):586\u2013604.","journal-title":"Statist Med"},{"issue":"8476","key":"6431_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"327","author":"J Martin Bland","year":"1986","unstructured":"Martin Bland J, Altman Douglas G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327(8476):307\u201310.","journal-title":"Lancet"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06431-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T03:09:09Z","timestamp":1662347349000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06431-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6431"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06431-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the IEC of the following sites: Comitato Etico Sapienza Universit\u00e0 di Roma (Italy), the Comit\u00e9 d\u2019Ethique hospitalo-facultaire of the Cliniques universitaires Saint-Luc (Belgium), the Ethik-Kommission II der Universit\u00e4t Heidelberg (Germany).Written informed consent will be provided by each participant before the start of study assessments or the intervention.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"CL, GDS, AM, OC, LGL, AT, IT, IFT, VW, and MW declare they have no competing interests. PBF was an employee of Gr\u00fcnenthal when she contributed to the study protocol, and reports consultancy fees from Consultech. IB is an employee of Gr\u00fcnenthal. SCC is an employee of Eli Lilly and Company. TL is an employee of Teva Pharmaceutical. NBF reports personal fees from Almirall, NeuroPN, Novartis Pharma, and Vertex and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics, outside the submitted work. EPZ reports fees from Mundipharma and Gr\u00fcnenthal, outside the submitted work. KP is an employee of Eli Lilly and Company. KS is an employee of Consultech. HVN was an employee of Gr\u00fcnenthal when he contributed to the protocol and reports personal fees from Medwis-extern GmbH & Co.KG, outside the submitted work. JMV is an employee of ESTEVE Pharmaceuticals. KV reports personal fees from Bayer Healthcare, Gr\u00fcnenthal, Eli Lilly and Company, and AbbVie, outside the submitted work. JV reports personal fees from Casquar, outside the submitted work. RDT reports personal fees from Bayer, Gr\u00fcnenthal, GSK, and Sanofi outside the submitted work. In addition, he has a patent DE 103 31 250.1-35 with royalties paid by MRC Systems. MRC Systems (BP and MG) develop, produce, and market products in the field of QST.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"739"}}